Literature DB >> 17069099

Effect of clarithromycin on cytokines and chemokines in children with an acute exacerbation of recurrent wheezing: a double-blind, randomized, placebo-controlled trial.

Monica Fonseca-Aten1, Pamela J Okada, Karen L Bowlware, Susana Chavez-Bueno, Asuncion Mejias, Ana Maria Rios, Kathy Katz, Kurt Olsen, Simon Ng, Hasan S Jafri, George H McCracken, Octavio Ramilo, R Doug Hardy.   

Abstract

BACKGROUND: Clarithromycin is postulated to possess immunomodulatory properties in addition to its antimicrobial activity.
OBJECTIVE: To evaluate the effect of clarithromycin on serum and nasopharyngeal cytokine and chemokine concentrations in children with an acute exacerbation of recurrent wheezing.
METHODS: Children with a history of recurrent wheezing or asthma and who presented with an acute exacerbation of wheezing were enrolled in a double-blind, randomized trial of clarithromycin vs placebo. Concentrations of tumor necrosis factor alpha (TNF-alpha), interferon-gamma (IFN-gamma), interleukin-1beta (IL-1beta), IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, granulocyte-macrophage colony-stimulating factor, RANTES, eotaxin, macrophage inflammatory protein 1alpha, macrophage inflammatory protein 1beta, and monocyte chemoattractant protein 1 were measured in serum and/or nasopharyngeal aspirates before, during, and after therapy. Mycoplasma pneumoniae and Chlamydophila pneumoniae infection were evaluated for by polymerase chain reaction and serologic testing.
RESULTS: Nasopharyngeal concentrations of TNF-alpha, IL-1beta, and IL-10 were significantly and persistently lower in children treated with clarithromycin compared with placebo. There tended to be a greater effect of clarithromycin on nasopharyngeal cytokine concentrations in patients with evidence of M. pneumoniae or C. pneumoniae infection. No significant differences were detected in serum cytokines for children treated with clarithromycin compared with placebo.
CONCLUSION: Clarithromycin therapy reduces mucosal TNF-alpha, IL-1beta, and IL-10 concentrations in children with an acute exacerbation of recurrent wheezing.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17069099     DOI: 10.1016/S1081-1206(10)60935-0

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  15 in total

1.  Efficacy of Macrolides on Acute Asthma or Wheezing Exacerbations in Children with Recurrent Wheezing: A Systematic Review and Meta-analysis.

Authors:  Mauricio A Pincheira; Leonard B Bacharier; Jose A Castro-Rodriguez
Journal:  Paediatr Drugs       Date:  2020-04       Impact factor: 3.022

2.  Mycoplasma pneumoniae in children with acute and refractory asthma.

Authors:  Pamela R Wood; Vanessa L Hill; Margaret L Burks; Jay I Peters; Harjinder Singh; Thirumalai R Kannan; Shruthi Vale; Marianna P Cagle; Molly F R Principe; Joel B Baseman; Edward G Brooks
Journal:  Ann Allergy Asthma Immunol       Date:  2013-02-23       Impact factor: 6.347

3.  Clarithromycin prevents preterm birth and neonatal mortality by dampening alarmin-induced maternal-fetal inflammation in mice.

Authors:  Jose Galaz; Roberto Romero; Marcia Arenas-Hernandez; Marcelo Farias-Jofre; Kenichiro Motomura; Zhenjie Liu; Naoki Kawahara; Catherine Demery-Poulos; Tzu Ning Liu; Justin Padron; Bogdan Panaitescu; Nardhy Gomez-Lopez
Journal:  BMC Pregnancy Childbirth       Date:  2022-06-20       Impact factor: 3.105

4.  Association of bacteria and viruses with wheezy episodes in young children: prospective birth cohort study.

Authors:  Hans Bisgaard; Mette Northman Hermansen; Klaus Bønnelykke; Jakob Stokholm; Florent Baty; Nanna Lassen Skytt; Julia Aniscenko; Tatiana Kebadze; Sebastian L Johnston
Journal:  BMJ       Date:  2010-10-04

5.  Macrolides for Acute Wheezing Episodes in Preschool Children.

Authors:  Hengameh H Raissy; Kathryn Blake
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2016-06-01       Impact factor: 1.349

6.  The impact of steroids given with macrolide therapy on experimental Mycoplasma pneumoniae respiratory infection.

Authors:  C Tagliabue; C M Salvatore; C Techasaensiri; A Mejias; J P Torres; K Katz; A M Gomez; S Esposito; N Principi; R D Hardy
Journal:  J Infect Dis       Date:  2008-10-15       Impact factor: 5.226

Review 7.  Newer treatments in the management of pediatric asthma.

Authors:  Paul D Robinson; Peter Van Asperen
Journal:  Paediatr Drugs       Date:  2013-08       Impact factor: 3.022

8.  Adverse events in people taking macrolide antibiotics versus placebo for any indication.

Authors:  Malene Plejdrup Hansen; Anna M Scott; Amanda McCullough; Sarah Thorning; Jeffrey K Aronson; Elaine M Beller; Paul P Glasziou; Tammy C Hoffmann; Justin Clark; Chris B Del Mar
Journal:  Cochrane Database Syst Rev       Date:  2019-01-18

9.  The efficacy of glucocorticoid on macrolide resistant Mycoplasma pneumonia in children.

Authors:  Jae-Won Oh
Journal:  Allergy Asthma Immunol Res       Date:  2013-12-23       Impact factor: 5.764

Review 10.  Antibiotics for exacerbations of asthma.

Authors:  Rebecca Normansell; Ben Sayer; Samuel Waterson; Emma J Dennett; Manuela Del Forno; Anne Dunleavy
Journal:  Cochrane Database Syst Rev       Date:  2018-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.